Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. Issue 9 (2nd September 2022)

• Record Type: Journal Article
• Authors: Cohen, Jared A; Ghobadi, Armin
• Is Part Of: Expert review of anticancer therapy. Volume 22:Issue 9(2022)
• Page Start: 903
• Page End: 914
• Publication Date: 2022-09-02
• Subjects: Follicular lymphoma -- axicabtagene ciloleucel -- CAR T-cell -- bispecific antibody -- indolent non-Hodgkin's lymphoma -- treatment -- cellular therapy; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2022.2096009
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an anti-CD20 monoclonal antibody with an alkylating agent, providing a therapeutic breakthrough in a subset of indolent non-Hodgkin lymphoma associated with poor clinical outcomes. Areas covered: In this article, we outline the drug profile of axicabtagene ciloleucel in comparison to currently approved agents and other CAR T-cell and T-cell redirecting therapies under investigation for the treatment of relapsed or refractory follicular lymphoma. We also review the efficacy, safety, and pharmacokinetic data from the ZUMA-5 phase II trial, which forms the basis of the recent approval of axicabtagene ciloleucel. Expert opinion: Axicabtagene ciloleucel is the first cellular therapy approved for relapsed or refractory follicular lymphoma, demonstrating high rates of durable responses and a manageable toxicity profile in heavily pre-treated patients.